CpG DNA as mucosal adjuvant.
We have previously found synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs to be a potent adjuvant to protein administered by intramuscular injection or intranasal inhalation to BALB/c mice. Herein we have further evaluated the potential of CpG ODN as a mucosal adjuvant to purified hepatitis B surface antigen (HBsAg) when administered alone or with cholera toxin (CT). CpG ODN and CT both augmented systemic (humoral and cellular) and mucosal immune responses against HBsAg, and these could be further enhanced with higher doses of adjuvant or boosting. Overall, antibody isotypes with CT alone were predominantly IgG1 (Th2-like) whereas they were predominantly IgG2a (Th1-like) with CpG ODN alone or in combination with CT. Results from this study indicate that stimulatory CpG ODN are promising new adjuvants for mucosal vaccination strategies, whether used alone or in combination with other mucosal adjuvants.
McCluskie
M J
MJ
Loeb Health Research Institute, 725 Parkdale Avenue, Ottawa, Canada.
Davis
H L
HL
D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D003596:Cytosine / Q000737:chemistry*; D004247:DNA / Q000235:genetics*; D005260:Female; D006147:Guanine / Q000737:chemistry*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D007117:Immunization, Secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000276:immunology
D000276:Adjuvants, Immunologic; D006514:Hepatitis B Surface Antigens; D006147:Guanine; D003596:Cytosine; D004247:DNA